×
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
S&P 500   3,825.33
DOW   31,097.26
QQQ   282.13
NASDAQ:ENTA

Enanta Pharmaceuticals Stock Forecast, Price & News

$49.63
+2.36 (+4.99%)
(As of 07/1/2022 12:00 AM ET)
Add
Compare
Today's Range
$47.20
$49.96
50-Day Range
$38.13
$70.00
52-Week Range
$37.59
$102.00
Volume
211,027 shs
Average Volume
249,802 shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$74.14

Enanta Pharmaceuticals Stock Forecast (MarketRank)

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
48.0% Upside
$73.43 Price Target
Short Interest
Bearish
10.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.44
Upright™ Environmental Score
News Sentiment
0.93mentions of Enanta Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$2.37 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.56) to ($3.64) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.81 out of 5 stars

Medical Sector

330th out of 1,429 stocks

Pharmaceutical Preparations Industry

135th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ENTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Enanta Pharmaceuticals logo

About Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.

ENTA Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ENTA
Employees
155
Year Founded
N/A

Company Calendar

Last Earnings
5/09/2022
Today
7/02/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
9/30/2022

Price Target and Rating

Average Stock Price Forecast
$73.43
High Stock Price Forecast
$103.00
Low Stock Price Forecast
$44.00
Forecasted Upside/Downside
+49.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71428571428571
Research Coverage
7 Analysts

Profitability

Net Income
$-79 million
Net Margins
-122.68%
Pretax Margin
-142.57%

Debt

Sales & Book Value

Annual Sales
$97.07 million
Book Value
$19.76 per share

Miscellaneous

Free Float
18,140,000
Market Cap
$1.03 billion
Optionable
Optionable
Beta
0.67














Enanta Pharmaceuticals Frequently Asked Questions

Should I buy or sell Enanta Pharmaceuticals stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Enanta Pharmaceuticals stock.
View analyst ratings for Enanta Pharmaceuticals
or view top-rated stocks.

What is Enanta Pharmaceuticals' stock price forecast for 2022?

7 Wall Street research analysts have issued twelve-month target prices for Enanta Pharmaceuticals' shares. Their ENTA stock forecasts range from $44.00 to $103.00. On average, they anticipate Enanta Pharmaceuticals' stock price to reach $73.43 in the next year. This suggests a possible upside of 48.0% from the stock's current price.
View analysts' price targets for Enanta Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

How has Enanta Pharmaceuticals' stock price performed in 2022?

Enanta Pharmaceuticals' stock was trading at $74.78 on January 1st, 2022. Since then, ENTA stock has decreased by 33.6% and is now trading at $49.63.
View the best growth stocks for 2022 here
.

When is Enanta Pharmaceuticals' next earnings date?

Enanta Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Enanta Pharmaceuticals
.

How were Enanta Pharmaceuticals' earnings last quarter?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) announced its quarterly earnings results on Monday, May, 9th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.43) by $0.20. The biotechnology company earned $18.72 million during the quarter, compared to the consensus estimate of $20.40 million. Enanta Pharmaceuticals had a negative trailing twelve-month return on equity of 28.80% and a negative net margin of 122.68%. During the same period last year, the company earned ($1.09) EPS.
View Enanta Pharmaceuticals' earnings history
.

Who are Enanta Pharmaceuticals' key executives?

Enanta Pharmaceuticals' management team includes the following people:
  • Dr. Jay R. Luly, Pres, CEO & Director (Age 66, Pay $1.23M)
  • Mr. Paul J. Mellett Jr., Sr. VP of Fin. & Admin. and CFO (Age 67, Pay $652.39k)
  • Dr. Yat Sun Or, Sr. VP of R&D and Chief Scientific Officer (Age 70, Pay $729.75k)
  • Ms. Tara Lynn Kieffer Ph.D., Sr. VP of New Product Strategy & Devel. (Age 44, Pay $496.85k)
  • Mr. Brendan Luu, Sr. VP of Bus. Devel.
  • Ms. Jennifer Viera, Sr. Director of Investor Relations & Corp. Communications
  • Mr. Nathaniel S. Gardiner J.D., Sr. VP, Gen. Counsel & Sec. (Age 68)
  • Dr. Nathalie Adda M.D., Consultant (Age 56) (LinkedIn Profile)

What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO?

3 employees have rated Enanta Pharmaceuticals CEO Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among Enanta Pharmaceuticals' employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Enanta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS).

What is Enanta Pharmaceuticals' stock symbol?

Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA."

How do I buy shares of Enanta Pharmaceuticals?

Shares of ENTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Enanta Pharmaceuticals' stock price today?

One share of ENTA stock can currently be purchased for approximately $49.63.

How much money does Enanta Pharmaceuticals make?

Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $1.03 billion and generates $97.07 million in revenue each year. The biotechnology company earns $-79 million in net income (profit) each year or ($5.52) on an earnings per share basis.

How many employees does Enanta Pharmaceuticals have?

Enanta Pharmaceuticals employs 155 workers across the globe.

How can I contact Enanta Pharmaceuticals?

Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for Enanta Pharmaceuticals is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at [email protected], or via fax at 617-607-0530.

This page (NASDAQ:ENTA) was last updated on 7/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.